Free tool
FAERS Monitor: Afinitor
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022334 or its brand name (Afinitor, Everolimus). Reports on generic versions are filed under their own applications.
Reports
49,330
Serious
38,255
78% of reports
Hospitalization
14,903
Death reported
10,696
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death6,201
- malignant neoplasm progression4,730
- diarrhoea4,043
- fatigue3,792
- stomatitis3,131
- nausea2,831
- dyspnoea2,603
- drug ineffective2,360
- decreased appetite2,113
- pyrexia2,107
- vomiting2,091
- rash1,985
- weight decreased1,924
- asthenia1,897
- cough1,867
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 5 |
| 2007 | 15 |
| 2008 | 34 |
| 2009 | 188 |
| 2010 | 928 |
| 2011 | 1,441 |
| 2012 | 2,329 |
| 2013 | 2,124 |
| 2014 | 2,289 |
| 2015 | 3,950 |
| 2016 | 4,796 |
| 2017 | 3,988 |
| 2018 | 4,749 |
| 2019 | 4,680 |
| 2020 | 4,217 |
| 2021 | 3,392 |
| 2022 | 2,678 |
| 2023 | 2,517 |
| 2024 | 2,108 |
| 2025 | 1,586 |
| 2026 | 1,313 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,004,829 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| stomatitisSignal | 3,131 | 23.2 | 22.4 | 63,103 |
| malignant neoplasm progressionSignal | 4,730 | 20.6 | 20.0 | 84,517 |
| decreased appetiteSignal | 2,113 | 3.9 | 3.7 | 4,573 |
| deathSignal | 6,201 | 3.1 | 3.0 | 9,037 |
| weight decreasedSignal | 1,924 | 3.0 | 2.8 | 2,497 |
| coughSignal | 1,867 | 2.9 | 2.7 | 2,257 |
| diarrhoeaSignal | 4,043 | 2.7 | 2.6 | 4,367 |
| pyrexiaSignal | 2,107 | 2.6 | 2.5 | 2,106 |
| astheniaSignal | 1,897 | 2.2 | 2.1 | 1,191 |
| fatigueSignal | 3,792 | 2.1 | 2.0 | 2,202 |
| dyspnoea | 2,603 | 2.0 | 1.9 | 1,261 |
| rash | 1,985 | 1.9 | 1.9 | 927 |
| vomiting | 2,091 | 1.9 | 1.8 | 907 |
| nausea | 2,831 | 1.5 | 1.5 | 533 |
| drug ineffective | 2,360 | 0.8 | 0.7 | 185 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.